204 related articles for article (PubMed ID: 35509127)
1. LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing
Peng T; Lin S; Meng Y; Gao P; Wu P; Zhi W; Ding W; Cao C; Wu P
Cell Cycle; 2022 Sep; 21(17):1827-1841. PubMed ID: 35509127
[TBL] [Abstract][Full Text] [Related]
2. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M
J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025
[TBL] [Abstract][Full Text] [Related]
3. LOXL2 in cancer: regulation, downstream effectors and novel roles.
Wen B; Xu LY; Li EM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
[TBL] [Abstract][Full Text] [Related]
5. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.
Peng DH; Ungewiss C; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Uraoka N; Mino B; Behrens C; Wistuba II; Han RI; Wanna CA; Fahrenholtz M; Grande-Allen KJ; Creighton CJ; Gibbons DL
Oncogene; 2017 Apr; 36(14):1925-1938. PubMed ID: 27694892
[TBL] [Abstract][Full Text] [Related]
6. Targeting lysyl oxidase like 2 attenuates OVA-induced airway remodeling partly via the AKT signaling pathway.
Zeng R; Zhang D; Zhang J; Pan Y; Liu X; Qi Q; Xu J; Xu C; Shi S; Wang J; Liu T; Dong L
Respir Res; 2024 Jun; 25(1):230. PubMed ID: 38824593
[TBL] [Abstract][Full Text] [Related]
7.
Yang YL; Tsai MC; Chang YH; Wang CC; Chu PY; Lin HY; Huang YH
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206143
[TBL] [Abstract][Full Text] [Related]
8. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL
Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405
[TBL] [Abstract][Full Text] [Related]
9. Lysyl oxidase-like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3.
Lu YJ; Deng YT; Ko HH; Peng HH; Lee HC; Kuo MY; Cheng SJ
Cancer Sci; 2023 Oct; 114(10):3957-3971. PubMed ID: 37496288
[TBL] [Abstract][Full Text] [Related]
10. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression.
Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y
Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697
[TBL] [Abstract][Full Text] [Related]
11. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
[TBL] [Abstract][Full Text] [Related]
12. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition.
de Jong OG; van der Waals LM; Kools FRW; Verhaar MC; van Balkom BWM
J Cell Physiol; 2019 Jul; 234(7):10260-10269. PubMed ID: 30387148
[TBL] [Abstract][Full Text] [Related]
13. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
[TBL] [Abstract][Full Text] [Related]
14. LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype.
Cao C; Lin S; Zhi W; Lazare C; Meng Y; Wu P; Gao P; Wei J; Wu P
Front Oncol; 2020; 10():284. PubMed ID: 32211324
[TBL] [Abstract][Full Text] [Related]
15. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
Hong X; Yu JJ
Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490
[TBL] [Abstract][Full Text] [Related]
16. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
17. LOXL2 Upregulation in Gliomas Drives Tumorigenicity by Activating Autophagy to Promote TMZ Resistance and Trigger EMT.
Zhang Q; Yang L; Guan G; Cheng P; Cheng W; Wu A
Front Oncol; 2020; 10():569584. PubMed ID: 33194658
[TBL] [Abstract][Full Text] [Related]
18. LOXL 2 Promotes The Epithelial-Mesenchymal Transition And Malignant Progression Of Cervical Cancer.
Tian J; Sun HX; Li YC; Jiang L; Zhang SL; Hao Q
Onco Targets Ther; 2019; 12():8947-8954. PubMed ID: 31802904
[TBL] [Abstract][Full Text] [Related]
19. Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy.
Ye M; Song Y; Pan S; Chu M; Wang ZW; Zhu X
Pharmacol Ther; 2020 Nov; 215():107633. PubMed ID: 32693113
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of lysyl oxidase and lysyl oxidase-like protein 2 suppressed the migration and invasion of trophoblasts by activating the TGF-β/collagen pathway in preeclampsia.
Xu XH; Jia Y; Zhou X; Xie D; Huang X; Jia L; Zhou Q; Zheng Q; Zhou X; Wang K; Jin LP
Exp Mol Med; 2019 Feb; 51(2):1-12. PubMed ID: 30804321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
